<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942068</url>
  </required_header>
  <id_info>
    <org_study_id>HR-HenanCH-OC019</org_study_id>
    <nct_id>NCT03942068</nct_id>
  </id_info>
  <brief_title>Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer</brief_title>
  <official_title>Evaluating the Efficacy and Safety of Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound&#xD;
      paclitaxel in patients with platinum-resistant recurrent ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open, one-arm, prospec will collect 35 patients with platinum-resistant&#xD;
      recurrent ovarian cancer treated with apatinib with albumin-bound paclitaxel from 2019 to&#xD;
      2020 in Henan Cancer Hospital.Antiangiogenic treatments have been implicated to play a major&#xD;
      role in ovarian cancer (OC). Apatinib, a novel oral antiangiogenic agent targeting vascular&#xD;
      endothelial growth factor receptor (VEGFR2), in combination with weekly paclitaxel, may&#xD;
      improve clinical outcomes compared with apatinib or paclitaxel alone in patients with&#xD;
      refractory or platinum-resistant ovarian cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>through study completion, an average of 5 year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>through study completion, an average of 5 year</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>albumin-bound paclitaxel+apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin-bound paclitaxel</intervention_name>
    <description>Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor</description>
    <arm_group_label>albumin-bound paclitaxel+apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)</description>
    <arm_group_label>albumin-bound paclitaxel+apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, age ≥18 years and ≤70 years, signed informed consent.&#xD;
&#xD;
          2. Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last&#xD;
             administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer&#xD;
             (defined as progressing while on a platinum-based chemotherapy).&#xD;
&#xD;
          3. At least treated with one line of platinum-based chemotherapy.&#xD;
&#xD;
          4. Imaging confirmed diagnosis of progression occurred after the last treatment before&#xD;
             enrollment.&#xD;
&#xD;
          5. Histologically or pathologically confirmed diagnosis of ovarian cancer as primary&#xD;
             tumor.&#xD;
&#xD;
          6. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             1.1 version.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.&#xD;
&#xD;
          8. Patients must have a life expectancy of at least 3 months.&#xD;
&#xD;
          9. Patients must have adequate organ function as defined by the following criteria:&#xD;
&#xD;
         10. White blood cell count ≥ 3 x 10^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x 10^9/L),&#xD;
             Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10^9/L, Total bilirubin ≤ 1 x upper limit of&#xD;
             normal (ULN), AST and ALT ≤ 2 x ULN, Serum creatinine ≤ 1 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Had prior exposure to apatinib or has known allegies to any of the excipients.&#xD;
&#xD;
             2.Patients with trauma, surgical history, gastrointestinal bleeding, and melena within&#xD;
             1 month prior to treatment.&#xD;
&#xD;
             3.Inadequately controlled hypertension. 4.History of abdominal fistula or&#xD;
             gastrointestinal perforation within 28 days prior to Day 1.&#xD;
&#xD;
             5.Imaging studies suggest that patients with tumors invading important blood vessels.&#xD;
&#xD;
             6.Symptomatic central nervous system (CNS) metastasis. 7.History of myocardial&#xD;
             infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV&#xD;
             within 6 months prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 5, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

